Table 4.
Histopathologic cure rate and reproductive outcomes in the following ET cycles of RIF/MDR-CE women treated with moxifloxacin versus azithromycin
| Moxifloxacin group (n = 24) | Azithromycin group (n = 24) | OR/95% CI/two-sided p value | |
|---|---|---|---|
| Histopathologic cure rate | 19/24 (79.2%) | 18/24 (75.0%) | 1.27/0.32 − 4.89/0.73 |
| ESPDI (mean ± SD) | 8.3 ± 2.1 | 7.8 ± 4.6 | -/-/0.63 |
| Immediate first ET cycle | |||
| Clinical pregnancy rate (per transfer) | 9/19 (47.4%) | 8/18 (44.4%) | 1.13/0.30 − 4.11/0.85 |
| Miscarriage rate (per clinical pregnancy) | 3/9 (33.3%) | 2/8 (25.0%) | 1.50/0.18 − 12.46/0.70 |
| Live birth rate (per transfer) | 6/19 (31.6%) | 6/18 (33.3%) | 0.92/0.23 − 3.66/0.91 |
| Cumulative three ET cycles | |||
| Clinical pregnancy rate (per transfer) | 16/38 (42.1%) | 15/34 (44.1%) | 0.92/0.36 − 2.35/0.86 |
| Miscarriage rate (per clinical pregnancy) | 5/16 (31.3%) | 4/15 (26.7%) | 1.25/0.26 − 5.94/0.78 |
| Live birth/ongoing pregnancy rate (per transfer) | 11/38 (28.9%) | 11/34 (32.4%) | 0.85/0.31–2.33/0.75 |
| Live birth/ongoing pregnancy rate (per couple)a | 11/19 (57.9%) | 11/18 (61.1%) | 0.88/0.23 − 3.26/0.84 |
aLive birth was confirmed in nine patients of the moxifloxacin group and 12 patients in the azithromycin group as of September 30, 2021